Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome

Patrick Altmann 1, Desiree De Simoni 1,2, Alexandra Kaider 3, Birgit Ludwig 1, Jakob Rath 1, Fritz Leutmezer 1, Fritz Zimprich 1, Romana Hoeftberger 1,2, Michael P. Lunn 4, Amanda Heslegrave 5,6, Thomas Berger 1, Henrik Zetterberg 5,6,7,8 and Paulus Stefan Rommer 1*

Abstract

Background: Guillain-Barré syndrome (GBS) is an autoimmune disease that results in demyelination and axonal damage. Five percent of patients die and 20% remain significantly disabled on recovery. Recovery is slow in most cases and eventual disability is difficult to predict, especially early in the disease. Blood or cerebrospinal fluid (CSF) biomarkers that could help identify patients at risk of poor outcome are required. We measured serum neurofilament light chain (sNfL) concentrations from blood taken upon admission and investigated a correlation between sNfL and clinical outcome.

Methods: Baseline sNfL levels in 27 GBS patients were compared with a control group of 22 patients with diagnoses not suggestive of any axonal damage. Clinical outcome parameters for GBS patients included (i) the Hughes Functional Score (HFS) at admission, nadir, and discharge; (ii) the number of days hospitalised; and (iii) whether intensive care was necessary.

Results: The median sNfL concentration in our GBS sample on admission was 85.5 pg/ml versus 9.1 pg/ml in controls. A twofold increase in sNfL concentration at baseline was associated with an HFS increase of 0.6 at nadir and reduced the likelihood of discharge with favourable outcome by a factor of almost three. Higher sNfL levels upon admission correlated well with hospitalisation time ($r_s = 0.69, p < 0.0001$), during which transfer to intensive care occurred more frequently at an odds ratio of 2.4. Patients with baseline sNfL levels below 85.5 pg/ml had a 93% chance of being discharged with an unimpaired walking ability.

Conclusions: sNfL levels measured at hospital admission correlated with clinical outcome in GBS patients. These results represent amounts of acute axonal damage and reflect mechanisms resulting in disability in GBS. Thus, sNfL may serve as a convenient blood-borne biomarker to personalise patient care by identifying those at higher risk of poor outcome.

Keywords: Guillain-Barré syndrome, Biomarker, Neurofilament, Prognosis, Outcome

* Correspondence: paulus.rommer@meduniwien.ac.at
1Department of Neurology, Medical University of Vienna, Vienna, Austria
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
The prognosis in some cases of Guillain-Barré syndrome (GBS) is rather poor—a fact partly attributed to the challenge of identifying these patients early in their presentation. Despite immunotherapy, one in five remains severely disabled. The mortality rate is 5% and mainly driven by complications requiring transfer to an intensive care unit (ICU) [1–3]. The diagnosis of GBS remains clinical, yet it is interlaced with published criteria for GBS that encompass nerve conduction studies (NCS) and analyses of cerebrospinal fluid (CSF) [4, 5]. Treatment strategies rely on early diagnosis; plasma exchange shortens time to neurological improvement, with intravenous immunoglobulin being equivalent. The highest efficacy is achieved when treatment started within 2 weeks from disease onset [6–9]. Although recent research has put the complement system under the microscope, no significant alterations to prognosis were accomplished in the past 30 years [10, 11].

Outcome prediction in patients with GBS is difficult due to a substantial variation in phenotypes. A few outcome scores provide some early prognostic data based on clinical presentation [12, 13]. However, there are currently no early predictive fluid biomarkers available. Hence, there is an urgent need to discover reliable, valid, and easily measurable serum; plasma or urine biomarkers that would guide caregivers in their clinical decision endeavour.

Neurofilaments have aroused considerate attention in biomarker research in a variety of neurological disorders [14–17]. Cellular disruption results in release of axonal cytoskeletal protein family neurofilaments into the CSF and serum [18–20]. A few previous studies in small cohorts of GBS patients have demonstrated prognostic properties for neurofilament heavy chain (NfH) and light chain (NfL) levels [21–24].

In the present study, we used state-of-the-art single molecule array (Simoa) technology to determine serum NfL (sNfL) levels in both GBS patients and controls. We systematically studied hospital records of 27 patients with diagnoses of GBS and its variants and applied advanced statistical analyses to expose any possible associations of sNfL levels with GBS disease course. The results are discussed in terms of measured biomarker concentration upon hospital admission and outcome at discharge.

Methods
This study was approved by the ethics committee at the Medical University of Vienna (EK1283/2018).

Study population
For this retrospective study, we screened our local biobank for suspected diagnoses of GBS or acute inflammatory demyelinating polyradiculoneuropathy (AIDP) or acute motor axonal neuropathy (AMAN) or acute motor and sensory axonal neuropathy (AMSAN) or Miller-Fisher syndrome from April 2014 through February 2018. A total of 47 patients were identified. Reviewing these patients’ clinical reports, 27 cases were included in the final study based on pre-defined screening criteria (Fig. 1). Screening criteria consisted of concise documentation of clinical disease course with the presence of detailed reports for nerve conduction studies (NCS); documented neurological exams; CSF results and biobank blood obtained within 5
days of hospitalisation; no previous diagnosis of GBS or preceding treatment in another facility; age > 18; and no documented comorbidities that would be indicative of altered sNfL levels (such as multiple sclerosis, any neurodegenerative disorder, stroke, seizure disorders, brain and spinal cord trauma, brain and spinal cord tumours, any neuropathy, congenital neurological disorders). Finally, only patients meeting levels 1 or 2 of the Brighton criteria were included [25]. Serum samples from 22 patients without any known axonal damage (benign intracranial hypertension and psychiatric disorders excluding dementia) served as a control group.

Extraction of clinical and paraclinical data
We extracted the following parameters from the electronic patient documentation system: (i) the Hughes Functional Score (HFS), a neurological evaluation score on general functioning in GBS patients, ranging from 0 (normal health), 1 (minor neurological symptoms or signs, being able to run), 2 (able to walk at least 5 m, but unable to run), 3 (able to walk 5 m with roller or support), 4 (bedridden), 5 (ventilated), to 6 (dead) [8]. HFS was calculated at admission (HFS*a), nadir (HFS*n) and discharge (HFS*d); (ii) detailed results from NCS with classification according to the Hadden criteria (that is primary demyelinating, primary axonal, inexcitable, equivocal or normal) [4]. These electrophysiology reports and the classification of GBS (and its variants) were confirmed by an investigator blinded to the clinical data based on standard nerve conduction studies of motor nerves including measurement of distal motor latency, CMAP amplitude and proximal/distal CMAP amplitude ratio, motor conduction velocity and minimal F wave latency; (iii) important results from the CSF analysis (cell count, total protein levels); (iv) evidence whether GBS onset was associated with a preceding infection (upper respiratory tract infection or diarrhoea); (v) information on treatment strategies and (vi) results from testing for anti-ganglioside antibodies.

Blood sampling
Serum samples were obtained within 5 days after symptoms of sensorimotor weakness occurred. Peripheral venous blood was collected in Greiner Bio-One Vacuette serum tubes (GBO, Kremsmuenster, Austria) and sent to the local biobank where the blood was processed according to standard operating procedures in an ISO 9001-certified environment as described previously [26]. In brief, tubes were centrifuged at 1.884×g for 10 min at room temperature after clotting had completed. Serum was then transferred to virgin polypropylene tubes in 400 μL aliquots and subsequently stored at −70°C until analysis.

Analysis of serum neurofilament light chain concentrations
For NfL measures, samples were thawed for 60 min at room temperature and were analysed by an investigator blinded to clinical data using the Simoa NF-light kit in the Simoa HD-1 Analyser (Quanterix, Lexington, MA, USA), which runs ultrasensitive paramagnetic bead-based enzyme-linked immunosorbent assays [27]. For this protocol, briefly, thawed samples and calibrators were dispensed in provided 96-well plates as duplicates. Further sample processing (dilution, incubation, washing, shaking, resuspending and reading) was carried out in an automated manner as described elsewhere [28]. The sNfL assay was carried out according to the manufacturer’s instructions and protocol.

Statistical analyses
Continuous variables are described by the mean (±SD) or the median value (interquartile range, IQR) in case of non-normal distributions. Due to the skewed distribution of sNfL, we used log2-transformed values for statistical analyses. To investigate differences in sNfL levels in GBS patients compared with controls, the unpaired t test was used, and analyses of covariance were applied to adjust the comparison for the possible confounder age and sex. To describe the association between sNfL and age, the Pearson correlation coefficient (r_p) was calculated. The association of sNfL, with CSF protein, albumin index, HFS and duration of hospitalisation, is described by the Spearman correlation coefficient (r_s). The duration of hospitalisation was set to the maximum value for two patients who had died at the ICU. Separate univariate and multivariable linear regression models were performed to evaluate the influence of sNfL on HFS*a and HFS*n, respectively. The HFS*a (HFS*n) value was considered as dependent variable and sNfL (log2 transformed) as independent explanatory variable. In the multivariable models, age (in years) and detection of a preceding infection (yes vs. no) were additionally included as explanatory variables. Since 74% of the patients in our cohort had HFS*d values ≥ 1, the binary outcome variable HFS*d = 1 vs. ≥ 2 was analysed using univariate logistic regression analyses. No adjustment was possible due to the small number of patients with HFS*d values ≥ 2. Univariate and multivariable Cox regression models were used to evaluate the influence of sNfL on the duration of hospitalisation, where two patients who had died at the ICU were censored at a maximum value. Age and preceding infection were included in addition to sNfL as explanatory variables in the multivariable regression model. Furthermore, univariate logistic regression model was performed to evaluate the prognostic value of sNfL on the probability of a transfer to an ICU, including receiver operating characteristic (ROC) curve analyses. Two-sided p values < 0.05 were considered
statistically significant. The software used was the SAS version 9.4 (SAS Institute Inc. (2016), Cary, NC, USA).

Results
Clinical history and nerve conduction were compatible with the diagnosis of GBS
All 27 patients fulfilled levels 1 or 2 of the Brighton diagnostic criteria regarding their clinical presentation: bilateral and flaccid weakness of the limbs, decreased or absent deep tendon reflexes, monophasic course and no alternative explanation for their symptoms. Out of these GBS patients, preceding infection was reported in 18/27 patients. As for the electrophysiological GBS classification, NCS reports from all 27 patients were available and compatible with diagnoses of GBS. All NCS reports were re-evaluated according to current diagnostic criteria. Nine reports showed missing single values and could not be re-verified, as machines were updated and protocols changed. Yet still, they all confirmed the diagnosis of GBS. Demographic information, results from nerve electrophysiology, sNfL levels on admission, CSF results, information on treatment strategies and results from anti-ganglioside antibody testing are given in Table 1. Neurophysiological features in our samples were heterogeneous. Seventeen patients showed a primary demyelinating pattern, five patients exhibited primary axonal changes and five patients had equivocal abnormalities. Due to small sample size across these three groups, no statistical calculations were possible. We found positive test results for antiganglioside antibodies in three non-demyelinating variants of GBS. Based on their clinical presentation, results from NCS and antiganglioside antibodies, we classified all 17 patients with primary demyelinating features as AIDP and two patients with primary axonal abnormalities on NCS as AMAN and one as AMSAN.

sNfL levels are higher in patients with GBS in comparison with controls
In order to investigate differences in sNfL levels in GBS patients compared with non-inflammatory controls, we calculated medians and means for both groups. The median (IQR) sNfL concentration on admission in the GBS group was 85.5 pg/ml (41.5–229.7 pg/ml) which distinguished them from controls that had a median concentration of 9.1 pg/ml (6.9–11.2 pg/ml, t test; p < 0.0001 (Fig. 2). CSF results from our control cohort suggested no presence of inflammatory activity based on cell count (2.0 [2–4]) and total protein (32.7 pg/ml [23.5–42.6 pg/ml]).

sNfL in GBS show some correlation with conventional CSF parameters
Seventeen of 27 GBS patients showed albumin-cytological dissociation in the CSF, so we tested for an association between sNfL and conventional CSF parameters such as total protein and albumin index. The calculated medians (IQR) were 54.8 pg/ml (45.4–76.4 pg/ml) for CSF protein and 12.6 ([× 1000], 5.3–15.8) for the albumin index. Correlations of these parameters with sNfL were moderate in both cases (Spearman correlation coefficients rs = 0.48; p = 0.016 for CSF protein and rs = 0.57; p = 0.002 for albumin index), reflecting the increased permeability of the blood nerve and blood brain barrier and some transit of proteins between compartments.

Consideration of age and sex in our study cohorts
A correlation of sNfL and age has been reported previously, and thus we tested for sex as a confounder in both our study cohorts [29, 30]. The mean age in the GBS group was 55 years ± 19 (range 20–80 years) and 36 years ± 13 (range 18–60 years) in the control group. Analysis of covariance suggests no influence of age (p = 0.95) and sex (p = 0.60) on sNfL concentrations, whereas the age- and sex-adjusted group difference was preserved (p < 0.0001). In our control group, age and sNfL levels were clearly associated (rs = 0.60, p = 0.0004) which was not the case for our GBS patients (rs = −0.11, p = 0.587).

Treatment strategies
Patients were treated with IV Ig, PE or a combination of both. All 27 patients were treated with IV Ig. Sixteen (59.3%) patients were treated with IV Ig alone and nine patients (33.3%) underwent additional PE. Ten patients were transferred to an ICU, eight of them received IV Ig and PE concomitantly, two of them did not undergo PE.

sNfL levels correspond to neurological function
In order to quantify neurological deficit in our GBS patients, HFS was calculated at admission (HFS*a), nadir (HFS*n) and hospital discharge (HFS*d) and related to sNfL levels upon admission. The median HFS values for these three time points were HFS*a = 3 (range 1–4), HFS*n = 3 (range 1–6) and HFS*d = 1 (range 1–6, Table 2). We found a moderate correlation between sNfL levels and HFS*a (Spearman correlation coefficient rs = 0.52; p = 0.005; Fig. 3a), HFS*n (rs = 0.59; p = 0.001; Fig. 3b) and HFS*d (rs = 0.41; p = 0.04). As for the HFS at discharge, we dichotomised it into HFS = 1 and HFS ≥ 2 and found that sNfL levels at the time of clinical diagnosis were able to differentiate these groups (odds ratio [OR] per twofold increase, 2.71 [95%CI 1.10–6.67]; p = 0.03; Fig. 3c). Effects of sNfL on the outcome HFS*a were 0.29 ± 0.09 (β ± SE, p = 0.004) in the univariate (unadjusted) and 0.28 ± 0.09 (β ± SE, p = 0.006) in the multivariable (adjusted for age and preceding infection) linear regression model. For HFS*n, our analysis yielded a parameter estimate of 0.60 ± 0.15 (β ± SE, p = 0.0006) in the univariate (unadjusted) model.
| Patient no. | Sex | Age | sNfL (pg/ml) | CSF dissoc. | CSF protein | Albumin index | NCS | Diagnostic certainty | Treatment | Ganglioside |
|------------|-----|-----|--------------|-------------|-------------|---------------|------|----------------------|-----------|------------|
| 1          | m   | 53  | 88.9         | No          | 34.1        | 4.2           | Primary demyelinating | 2         | IVIg      | Neg        |
| 2          | f   | 80  | 246.4        | Yes         | 119.8       | 23.2          | Primary demyelinating | 1         | IVIg      | Neg        |
| 3          | m   | 48  | 238.0        | No          | 44.3        | 5.5           | Primary demyelinating | 2         | IVIg, PE, ICU | Neg        |
| 4          | m   | 65  | 65.0         | Yes         | 54.8        | 12.6          | Primary demyelinating | 2         | IVIg      | Neg        |
| 5          | m   | 77  | 57.8         | No          | 43.4        | 5.8           | Primary demyelinating | 2         | IVIg, PE, ICU | Neg        |
| 6          | f   | 59  | 45.0         | Yes         | 68.8        | 12.6          | Primary demyelinating | 1         | IVIg      | Neg        |
| 7          | f   | 74  | 135.3        | Yes         | 175.6       | 35.0          | Primary demyelinating | 1         | IVIg, ICU | Neg        |
| 8          | f   | 45  | 71.7         | No          | 36.0        | 5.2           | Primary demyelinating | 2         | IVIg      | Neg        |
| 9          | m   | 52  | 77.3         | Yes         | 57.2        | 12.9          | Primary demyelinating | 1         | IVIg      | Neg        |
| 10         | m   | 65  | 17.9         | Yes         | 53.2        | 8.9           | Primary demyelinating | 1         | IVIg      | Neg        |
| 11         | m   | 37  | 383.0        | Yes         | 67.5        | 17.8          | Primary demyelinating | 1         | IVIg, PE | Neg        |
| 12         | m   | 20  | 229.7        | Yes         | 76.7        | 12.9          | Primary demyelinating | 1         | IVIg, PE, ICU | Neg        |
| 13         | m   | 54  | 204.5        | No           | 47.4        | 17.3          | Primary demyelinating | 1         | IVIg, PE, ICU | Neg        |
| 14         | m   | 70  | 41.5         | No           | 45.1        | 5.3           | Primary demyelinating | 2         | IVIg      | Neg        |
| 15         | m   | 74  | 249.0        | Yes         | 55.2        | 15.8          | Primary demyelinating | 1         | IVIg      | Neg        |
| 16         | f   | 22  | 499.8        | Yes         | 157.8       | 34.9          | Primary demyelinating | 1         | IVIg, PE, ICU | Neg        |
| 17         | m   | 73  | 146.6        | Yes         | 70.5        | 14.0          | Primary demyelinating | 1         | IVIg      | Neg        |
| 18         | w   | 30  | 30.7         | Yes         | 16.7        | 2.3           | Primary axonal        | 2         | IVIg      | GM1        |
| 19         | f   | 78  | 12.9         | No           | 45.3        | 6.0           | Primary axonal        | 1         | IVIg      | Neg        |
| 20         | m   | 66  | 85.5         | Yes         | 102.5       | 21.0          | Primary axonal        | 1         | IVIg      | Neg        |
| 21         | f   | 66  | 46.7         | No           | 28.5        | 4.6           | Primary axonal        | 2         | IVIg, PE, ICU | GM1        |
| 22         | m   | 30  | 139.0        | No           | 32.1        | 4.6           | Primary axonal        | 2         | IVIg, PE, ICU | GD1a       |
| 23         | m   | 31  | 17.2         | Yes         | 86.5        | 14.0          | Equivocal             | 1         | IVIg      | Neg        |
| 24         | f   | 40  | 82.6         | Yes         | 74.2        | 13.6          | Equivocal             | 1         | IVIg      | Neg        |
| 25         | f   | 34  | 18.6         | Yes         | 30.2        | 4.1           | Equivocal             | 1         | IVIg      | Neg        |
| 26         | m   | 74  | 210.5        | No           | 46.8        | 9.7           | Equivocal             | 1         | IVIg, ICU | Neg        |
| 27         | w   | 59  | 684.7        | Yes         | 76.4        | 13.0          | Equivocal             | 1         | IVIg, PE, ICU | Neg        |

Analysed data from this study cohort (n = 27): demographic information, serum neurofilament light chain (sNfL) concentration upon admission, CSF results (albumin-cytological dissociation, total CSF protein count [mg/dl] and albumin index [× 1000]), results from nerve conduction studies (NCS) according to Hadden criteria [4], the level of diagnostic certainty (Brighton criteria [25]), information on the treatment strategy (IVIg intravenous immunoglobulin; PE plasma exchange; ICU transfer to an intensive care unit) and results from anti-ganglioside antibody testing.
sNfL levels on admission predict duration of hospitalisation and ICU transfer

We evaluated the duration of hospitalisation and indications for referrals to an intensive care unit. The median number of hospitalised days was 30 (range 13–66 days) in the GBS group. Higher sNfL levels on admission correlated with a longer hospitalisation time ($r_s = 0.69; p < 0.0001$ Fig. 4a). Cox regression estimated a hazard ratio (HR) of 0.62 (95% CI 0.46–0.85; $p = 0.003$), revealing a lower chance of early discharge from the hospital with higher sNfL levels. This relation was independent of age and a preceding infection, with an adjusted HR of 0.60 (95% CI 0.44–0.82; $p = 0.001$). Ten of 27 patients were transferred to an ICU. The likelihood of this intervention was associated with raised sNfL concentration on admission with an odds ratio of 2.37 (95% CI 1.14–4.95 Fig. 4b). The prognostic importance was evaluated performing a ROC (receiver operating characteristic) curve analysis and revealed an AUROC (area under the ROC curve) of 0.78 (95% CI 0.60–0.96 Fig. 4c).

sNfL levels deviating from the median illustrate a different outcome

In a different approach to prognosis, we calculated patient outcome for baseline sNfL levels below and above the median. As described before, the median sNfL concentration in our sample was at 85.5 pg/ml. For the investigation of potential differences in outcome above and below this threshold, we analysed the frequency distribution of the following parameters: hospitalisation days, HFS and ICU transfer. Patients with sNfL levels below the median had a median hospital stay of 13.5 days, versus 78 days in the group with sNfL above the median. The median HFS score at nadir was 2 (=able to walk at least 5 m) for patients below that threshold and 5 (=ventilated) for patients above that threshold. Correspondingly, patients with a baseline sNfL concentration above the median in our sample were transferred to an ICU more frequently (62%)

Table 2 Functional performance throughout the hospital stay

| HFS | HFS*a n (%) | HFS*n n (%) | HFS*d n (%) |
|-----|-------------|-------------|-------------|
| 1   | 5 (19)      | 4 (15)      | 20 (74)     |
| 2   | 7 (26)      | 5 (19)      | 1 (4)       |
| 3   | 13 (48)     | 6 (22)      | 3 (11)      |
| 4   | 2 (7)       | 2 (7)       | 1 (4)       |
| 5   | 0 (0)       | 8 (30)      | 0 (0)       |
| 6   | 0 (0)       | 2 (7)       | 2 (7)       |

Distribution of the calculated values for the Hughes Functional Score (HFS) on admission (HFS*a) at nadir (HFS*n) and discharge (HFS*d)

n the absolute number
% the percentage
than patients below the median (14%). Results from this descriptive analysis are given in Table 3.

**Discussion**

Although the diagnosis of Guillain-Barré syndrome is well established by means of clinical criteria with supportive electrophysiology and CSF investigations, a convenient and reliable biomarker for the prediction of clinical outcome or prognosis is still needed. In current literature, the potential of NfL as a biomarker in a variety of neurological diseases including neuropathies is being discussed. A recent study based on a sample of 25 patients with acquired neuropathies, including five cases of GBS, suggested NfL as a potential biomarker in correlation with the patients’ disability [24]. Another study with 18 patients showed that high NfL concentrations in cerebrospinal fluid at onset of GBS may predict long-term disability, thus, reflecting affirmatively on the mechanisms of axonal damage in this disease [21]. We think our present investigation of 27 patients, though different in design and hypotheses, compares well to this observation by suggesting NfL concentrations in serum to be linked with neurological impairment or burden of hospitalisation.

We demonstrated that sNfL levels, obtained upon admission, were increased compared with controls. In addition, we found that sNfL levels are clearly correlated...
with parameters for disease severity and indicative of the duration of hospitalisation and the risk of transfer to an ICU. With regard to functional outcome, we found in univariate (unadjusted) linear regression models that a twofold higher sNfL concentration upon admission resulted in a HFS-increase of 0.3 on admission and 0.6 at nadir. This was confirmed in the multivariable (adjusted) linear regression models. As for the HFS on discharge, our results indicate that doubling the sNfL concentration upon admission makes it almost three times more likely to have a less favourable outcome (HFS ≥2). Furthermore, higher sNfL levels on admission correlated strongly with duration of hospitalisation ($r_s = 0.69$, $p < 0.0001$). Our calculations estimated an HR per twofold increase of 0.62, implying that the likelihood of discharge is reduced to 62% when the sNfL concentration on admission doubles. Respectively, baseline sNfL levels were associated with the need of intensive care: ICU transfer occurred at an OR per twofold increase of 2.37, showing that transfer to ICU was about 2.4 times more likely when the sNfL concentration on admission doubles. The median sNfL concentration on admission was 85.5 pg/ml, a value well in line with another study that reported a median of 84.7 pg/ml in acute neuropathies including five cases of GBS [24]. In order to illustrate the potential of sNfL as an indicator for disease course, we calculated our defined outcome parameters (hospitalisation time, Hughes Functional Score, ICU transfer) for a threshold of below and above the median. By means of this model, descriptive analyses demonstrated that the median number of days spent in the hospital were six times higher above that set threshold. The chance of being discharged with an unimpaired walking ability was 93% for patients with sNfL levels below 85 pg/ml upon admission. Also, the likelihood of complications leading to ICU transfer was only 14%.

There are some limitations of our study. We were constrained to relating our data exclusively to patient records evaluated retrospectively and to a single biomarker measure upon admission. However, accuracy of diagnosis was ascertained by applying selective screening criteria. Our controls were carefully selected to reflect conditions without CSF inflammation or likely axonal damage. Though our studied GBS cohort is indeed the largest one to date, the sample size is small. In our tertiary care hospital we see about eight to ten cases of GBS per year which we regard as a representative patient collective for Austria with a reported incidence of GBS of 1/100,000 [31, 32]. Our cohort consisted of 27 participants. Yet, in comparison with other studies on both blood and CSF derived neurofilaments in GBS (two studies on NfH and one on NfL) with sample sizes ranging from 3 to 18, our number of enrolled patients suggests reasonable validity [21, 23, 24]. Also, our predictive model did not aim at giving a strict cut-off. We rather intended to approximate an idea of a range of sNfL concentration that indicates a shift in patient outcomes and we were able to show how patient outcomes worsened with increasing sNfL concentrations. In addition, 10 of 27 patients were transferred to an ICU, a number slightly higher than previously reported [2, 33]. Eight of these transferred patients underwent PE (vs. one patient receiving PE on regular care). It would be interesting to adjust for this possibly confounding factor; yet, due to our small sample size and the retrospective design of this study, we cannot fully distinguish the reasons for this observation. In any case, clinical status was attributable in this regard: The patient’s worst clinical status (as indicated by the outcome HFS*p) seemed different in those patients transferred to ICU. Their median (IQR) HFS*p scores were 5 [3] vs. 2 [2, 3] in those not transferred. Procedural considerations may also have played a role, as patients undergoing PE were, apparently, more likely to be moved to intensive care as opposed to patients treated with immunoglobulin.

The findings from our study are relatable to current literature and reveal new aspects with respect to sNfL as a biomarker in GBS [13, 32, 34]. Interestingly, age did impact sNfL concentrations in our control group but not in our patient cohort. Control patients showed a clear association between sNfL and age ($r_p = 0.60$, $p = 0.0004$), whereas the GBS group did not ($r_p = 0.11$, $p = 0.587$). This is very likely to be due to the significant increase in NFL levels and decreased integrity of the blood nerve and blood brain barrier which supervenes any normal physiological protein distribution. We also found that sNfL concentrations did not seem to differ between the subtypes of AIDP and axonal variants which are somewhat curious. Though sample size is too small to draw any conclusions, we believe that sNfL are

**Table 3** Patient outcomes for baseline sNfL levels below and above the median

| sNfL ≤ 85.5 pg/ml | sNfL > 85.5 pg/ml |
|-------------------|-------------------|
| n = 14            | n = 13            |
| Hospitalisation days† | 13.5 (11–20) | 78 (46–92) |
| HFS*a†            | 2 (1–3)          | 3 (3–3)   |
| HFS*n†            | 2 (1–3)          | 5 (4–5)   |
| HFS*d†            | 1 (1–1)          | 1 (1–3)   |
| HFS*d = 1†        | 13 (93%)         | 7 (54%)   |
| ICU transfer†: yes | 2 (14%)          | 8 (62%)   |
| ICU transfer†: no  | 12 (86%)         | 5 (38%)   |

*Descriptive analysis of different outcome parameters below and above the median sNfL concentration upon admission HFS*a Hughes Functional Score on admission, HFS*n Hughes Functional Score at discharge, ICU intensive care unit, HFS*d Hughes Functional Score at nadir, HFS*d = 1 threshold is set at the median of 85.5 pg/ml sNfL > 85.5 pg/ml.*
elevated even in primarily demyelinating disease which might be attributed to axonal damage below the threshold detectable by nerve electrophysiology. Neuropathy may not represent what is really happening at the pathology level. Nodoparanodopathy has been described as an emerging concept of damaged peripheral nerves [35]. Neurofilaments may be leaking from many fibres that are being damaged long before electrophysiology is capable of determining an excess of axonal loss in NCS or electromyography. In a prospective study where we are able to look at eventual outcomes by late NCS or eventual disability outcomes it may be possible to discern this in a larger study.

In total, we were able to further add to findings from previous studies with respect to a more profound representation of the patients’ in-hospital disease course including rigorous evaluation of the diagnosis. We believe our results are of mediate relevance to caregivers and patients alike. With our data at hand, NFL levels detected early in serum of patients with GBS could enable individualised risk stratification and prognosis in the future. They may be synergistically useful when included in other clinical predictive models, such as the Erasmus GBS outcome scale (mEGOS) [12].

Conclusion
In this retrospective analysis, we show multifaceted associations between serum neurofilament light chain concentrations and outcomes in Guillain-Barré syndrome. This is the largest and most comprehensive study of NFL to date. We systematically analysed records of 27 GBS patients, compared them to well-defined controls and exposed correlations between sNFL and clinical outcome. Our predictive model revealed that patients with baseline levels below our sample’s median of 85 pg/ml had a 93% chance of being discharged with an unimpaired walking ability. Also, we found clear associations with hospitalisation days and the probability for ICU transfer.

We believe that the knowledge of this correlation will influence prognostic considerations in this rare disease. Not only could this spur further research endeavours targeting this biomarker’s role in GBS but it would also aid in the process of identifying patients at higher risk of poor outcome, thus, eventually resulting in a more aggressive therapeutic approach to these particular patients. We have initiated a prospective study with collaborators that shall validate this biomarker further. By relating to a longitudinal follow up that also accounts for quality of life of those affected, we believe that patient care can be improved in the future by recognising those at higher risk.

Abbreviations
AIDP: Acute inflammatory demyelinating polyradiculoneuropathy; AMAN: Acute motor axonal neuropathy; AMSAN: Acute motor and sensory axonal neuropathy; AUC: Area under the curve; CI: Confidence interval; CNS: Central nervous system; CSF: Cerebrospinal fluid; HFS: Hughes Functional Score; HFS*a: Hughes Functional Score at admission; HFS*d: Hughes Functional Score at discharge; HFS*n: Hughes Functional Score at nadir; HR: Hazard ratio; ICU: Intensive care unit; IQR: Interquartile range; IVIG: Intravenous immunoglobulin; NfH: Neurofilament heavy chain; NFL: Neurofilament light chain; OR: Odds ratio; PE: Plasma exchange; pg/ml: Picogram per millilitre; ROC: Receiver operating characteristic; SD: Standard deviation; Simoa: Single molecular array; sNFL: Serum neurofilament light chains

Acknowledgements
The authors would like to thank Raphael Wurm, MD (Medical University of Vienna, Department of Neurology), Miranda Stattmann (Medical University of Vienna, Department of Neurology) and Michael Chou (UCL Queen Square Institute of Neurology) for their technical assistance and Axel Petzold, MD, PhD (UCL Queen Square Institute of Neurology) for general advice.

Authors’ contributions
PA, PSR, FL, ML and FZ contributed to the study conception and design, PA, DOS and RH contributed to the acquisition of data. PA, BL, JR, FL, AH and HZ analysed and interpreted the data. AK conducted the statistical analyses. PA, FL and PSR were involved in writing the manuscript. TB, PSR, FL, MPL and HZ reviewed and revised the manuscript. All authors read and approved the final manuscript.

Funding
This study was funded by the Medical University of Vienna and the UK Dementia Research Institute at UCL.

Availability of data and materials
Data can be made available from the corresponding author upon reasonable request and after approval from the ethics review board at the Medical University of Vienna.

Ethics approval and consent to participate
This study was approved by the ethics committee at the Medical University of Vienna (1283/2018) and written informed consent for biobanking was obtained.

Consent for publication
Not applicable.

Competing interests
MPL is a member of the scientific advisory boards for CSL Behring, Novartis and UCB Pharma and has minor unconditional travel grants to relevant meetings from CSL Behring (all outside the submitted work). HZ is a member of the scientific advisory boards for Roche Diagnostics, Wave, Samumed and CoqHr; lectures in symposia sponsored by Biogen and Alzecure; and is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg (all outside the submitted work). The other authors declare that they have no competing interests.

Author details
1Department of Neurology, Medical University of Vienna, Vienna, Austria. 2Division of Neuropathology and Neurochemistry, Medical University of Vienna, Vienna, Austria. 3Center for Medical Statistics, Informatics and Intelligent Systems, Medical University of Vienna, Vienna, Austria. 4Neuroimmunology and CSF Laboratory, Institute of Neurology, University College London, London, UK. 5Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. 6The UK Dementia Research Institute at UCL, London, UK. 7Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden. 8Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Received: 20 October 2019 Accepted: 5 February 2020
Published online: 17 March 2020

References

1. Hughes RAC, Comblath DR, Willison HJ. Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. Brain. 2016;139:3041–7.
2. Yuki N, Hartung H-P. Guillain-Barré Syndrome. N Engl J Med. 2012;366:2294–304.
3. Hughes RAC, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245–57.
4. Hadden RDM, Comblath DR, Hughes RAC. Zielask J, Hartung H-P, Toika YV, Swan AV. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol. 1998;44:780–8.
5. van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.
6. Hughes RAC, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2006;(1):CD002063.
7. Raphael JC, Chevre S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002;(2):CD001798.
8. The Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet. 1997;349:225–30.
9. van der Meché FGA, Schmitz PIM. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med. 1992;326:1123–9.
10. Goodfellow JA, Willison HJ. Guillain–Barré syndrome: a century of progress. Nat Rev Neurol. 2016;12:723.
11. Misawa S, Kuwabara S, Sato Y, Yamaguchi N, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suchi T, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17:519–29.
12. van Koningsveld R, Steyerberg EW, Hughes RAC, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol. 2007;6:589–94.
13. Wu X, Li C, Zhang B, Shen D, Li T, Liu K, Zhang H-L. Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barré syndrome. Crit Care. 2015;19:310.
14. Bridel C, van Weringen WN, Zetterberg H, Tijms BM, Teunissen CE. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019. https://doi.org/10.1001/jamaneurol.2019.1534. [Epub ahead of print].
15. Gaertani I, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2018;92:50.
16. Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comella M, Fazekas F, et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14:577–89.
17. Zetterberg H. Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron. 2016;91:1–3.
18. Jülem J-P. Neurofilament functions in health and disease. Curr Opin Neurobiol. 1999;9:554–60.
19. Lee M, Xu Z, Wong P, Cleveland D. Neurofilaments are obligate heteropolymers in vivo. J Cell Biol. 1993;122:1337–50.
20. Petzold A. Neurofilament phosphofimins: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci. 2005;233:183–98.
21. Axellson M, Skögren M, Andersen O, Blennow K, Zetterberg H, Lycke J. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: a pilot study. Acta Neurol Scand. 2018;138:143–50.
22. Petzold A, Hinds N, Murray NF, Hirsch NP, Grant D, Keir G, Thompson EJ, Reilly MM. CSF neurofilament levels: a potential prognostic marker in Guillain-Barré syndrome. Neurology. 2006;67:1071–3.
23. Dujmovic I, Lunn MP, Reilly MM, Petzold A. Serial cerebrospinal fluid neurofilament heavy chain levels in severe Guillain-Barré syndrome. Muscle Nerve. 2013;48:132–4.
24. Mariotto S, Farinazzo A, Magliozi R, Alberti D, Monaco S, Ferrari S. Serum and cerebrospinal fluid neurofilament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst. 2018;23:174–7.